| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| Product Name: | MK 996 | | Synonyms: | MK 996;L-159282;Benzamide, N-[[4'-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl][1,1'-biphenyl]-2-yl]sulfonyl]-;3-((2'-(Benzoylaminosulfonyl)biphenyl-4-yl)methyl)-2-ethyl-5,7-dimethyl-3H-imidazo(4,5-B)pyridine | | CAS: | 157263-00-8 | | MF: | C30H28N4O3S | | MW: | 524.63 | | EINECS: | | | Product Categories: | | | Mol File: | 157263-00-8.mol |  |
| | MK 996 Chemical Properties |
| density | 1.27±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | pka | 4.70±0.10(Predicted) |
| | MK 996 Usage And Synthesis |
| Uses | L-159282 is a highly potent, orally active, nonpeptide angiotensin II receptor antagonist, with anti-hypertensive activity. | | in vivo | In the anesthetized chimpanzee, L-159282 (1 mg/kg, iv) produces 100% inhibition of the AII pressor response and is still active (52%) at 24 h. In aortic coarcted (high renin) rats, L-159282 (3 mg/kg, p.o.) reduces blood pressure to normotensive (< 120 mm Hg) levels without reflex tachycardia. This dose of L-159282 reduces blood pressure to approximately the same level as both losartan (3 mg/kg, p.o.) and enalapril (3 mg/kg, p.o.) in this model[1]. | | References | [1] Kivlighn SD, et al. In vivo pharmacology of a novel AT1 selective angiotensin II receptor antagonist, MK-996. Am J Hypertens. 1995 Jan;8(1):58-66. DOI:10.1016/0895-7061(94)00169-c |
| | MK 996 Preparation Products And Raw materials |
|